Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

LSTA - LISATA THERAPEUTICS, INC.


IEX Last Trade
2.77
0   0%

Share volume: 0
Last Updated: Thu 26 Dec 2024 02:58:27 PM CET
Research and Development in Biotechnology (except Nanobiotechnology): -0.11%

PREVIOUS CLOSE
CHG
CHG%

$2.77
0.00
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
4%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 10%
Performance
5 Days
2.48%
1 Month
8.98%
3 Months
8.60%
6 Months
-9.24%
1 Year
8.22%
2 Year
22.69%
Key data
Stock price
$2.77
P/E Ratio 
0.00
DAY RANGE
$2.77 - $2.99
EPS 
$0.00
52 WEEK RANGE
$2.66 - $3.83
52 WEEK CHANGE
$9.75
MARKET CAP 
23.628 M
YIELD 
N/A
SHARES OUTSTANDING 
8.320 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/31/2024
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$18,481
AVERAGE 30 VOLUME 
$19,277
Company detail
CEO: David J. Mazzo
Region: US
Website: caladrius.com
Employees: 30
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Caladrius Biosciences, Inc. focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia.

Recent news